New York City’s Testing Need
The success of New York City’s Test and Trace program has facilitated a safe and steady economic reopening; the City is seeking to significantly increase the availability, usability, and speed of testing to further reopen the economy in the period prior to broad distribution of a vaccine. Specifically, New York City seeks point-of-care and at-home COVID tests that can deliver results in minutes, rather than hours and that may be self-administered. There are only a handful of COVID tests that have Food and Drug Administration (FDA) Emergency Use Authorization (EUA) and are allowed in a CLIA-waived setting (“rapid tests”). However, many are in development and the FDA has recently issued guidance for at-home and over-the counter diagnostic tests.
To accelerate the development and deployment of rapid tests, New York City Economic Development Corporation (NYCEDC), on behalf of the City, is seeking to identify companies developing innovative molecular or antigen rapid tests that can deliver results quickly, reliably, and at scale. Diagnostic test manufacturers, suppliers, developers, and academics are invited to submit proposals per the below guidelines. Selected respondents may have the opportunity to advance product development through access to City resources. Such resources could include, without limitation, the expertise of health agencies, City-owned real estate assets for R&D and manufacturing, or contracts for purchase of rapid tests.
Final Submission Deadline was March 3rd, 2021
NYCEDC is no longer accepting submissions for the competition. NYCEDC will directly contact respondents it is interested in further assessing.
|Release of Competition||September 24, 2020|
|Final Submission Deadline||March 3, 2021|
Images: Matt Monath Photography